Abatacept AIMs to please: high standards ATTAINed in RA

New hope is on the horizon for patients with rheumatoid arthritis who have inadequate responses to disease-modifying anti-rheumatic drugs (DMARDs) such as methotrexate or tumour necrosis factor antagonists. Results from a number of studies presented at this year's joint meeting of the American College of Rheumatology (ACR) and the Association of Rheumatology Health Professionals (ARHP) [Boston, Massachusetts, US; November 2007] indicate that abatacept [Orencia] improves participation in daily activities, sleep quality, and physical and social role independence in such patients, and that these improvements are maintained over 5 years.